U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07515014) titled 'A Study of E6742 in Participants With Systemic Lupus Erythematosus' on March 11.
Brief Summary: The main purpose of the study is to demonstrate the efficacy based on dose response of E6742 compared with placebo as defined by the proportion of participants achieving a response using the British Isles Lupus Assessment Group (BILAG) based Composite Lupus Assessment (BICLA) with a low dose of oral corticosteroids (OCS) (prednisone or equivalent) at Week 24 in participants with systemic lupus erythematosus (SLE).
Study Start Date: March 31
Study Type: INTERVENTIONAL
Condition:
Systemic Lupus Erythematosus
Intervention:
DRUG: E6742...